Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. by Ahmed, HU et al.
622 www.thelancet.com/oncology   Vol 13   June 2012
Articles
Lancet Oncol 2012; 13: 622–32
Published Online
April 17, 2012
DOI:10.1016/S1470-
2045(12)70121-3
See Comment page 567
Division of Surgery and 
Interventional Science, 
University College London, 
London, UK (H U Ahmed MRCS, 
L Dickinson MRCS, R Scott RN, 
Prof M Emberton FRCS); 
Department of Urology 
(H U Ahmed, L Dickinson, 
M Sahu MRCS), Department of 
Histopathology 
(A Freeman FRCPath), and 
Department of Radiology 
(A P Kirkham FRCR, 
C Allen FRCR), University 
College London Hospitals NHS 
Foundation Trust, London, UK; 
Department of Urology, 
Hampshire Hospitals NHS 
Foundation Trust, Basingstoke, 
UK (R G Hindley FRCS); Clinical 
Eﬀ ectiveness Unit, Royal 
College of Surgeons of England, 
London, UK 
(Prof J Van der Meulen PhD); and 
Health Services Research Unit, 
The London School of Hygiene 
and Tropical Medicine, London, 
UK (Prof J Van der Meulen)
Correspondence to:
Dr Hashim Uddin Ahmed, 
Division of Surgery and 
Interventional Sciences, 
University College London, 
67 Riding House Street, 
London, W1P 7NN, UK
hashim.ahmed@ucl.ac.uk
Focal therapy for localised unifocal and multifocal prostate 
cancer: a prospective development study
Hashim U Ahmed, Richard G Hindley, Louise Dickinson, Alex Freeman, Alex P Kirkham, Mahua Sahu, Rebecca Scott, Clare Allen, 
Jan Van der Meulen, Mark Emberton
Summary
Background Radical whole-gland therapy can lead to signiﬁ cant genitourinary and rectal side-eﬀ ects for men with 
localised prostate cancer. We report on whether selective focal ablation of unifocal and multifocal cancer lesions can 
reduce this treatment burden.
Methods Men aged 45–80 years were eligible for this prospective development study if they had low-risk to high-risk 
localised prostate cancer (prostate speciﬁ c antigen [PSA] ≤15 ng/mL, Gleason score ≤4 + 3, stage ≤T2), with no previous 
androgen deprivation or treatment for prostate cancer, and who could safely undergo multiparametric MRI and have 
a general anaesthetic. Patients received focal therapy using high-intensity focused ultrasound, delivered to all known 
cancer lesions, with a margin of normal tissue, identiﬁ ed on multiparametric MRI, template prostate-mapping 
biopsies, or both. Primary endpoints were adverse events (serious and otherwise) and urinary symptoms and erectile 
function assessed using patient questionnaires. Analyses were done on a per-protocol basis. This study is registered 
with ClinicalTrials.gov, number NCT00561314.
Findings 42 men were recruited between June 27, 2007, and June 30, 2010; one man died from an unrelated cause 
(pneumonia) 3 months after treatment and was excluded from analyses. After treatment, one man was admitted 
to hospital for acute urinary retention, and another had stricture interventions requiring hospital admission. 
Nine men (22%, 95% CI 11–38) had self-resolving, mild to moderate, intermittent dysuria (median duration 5·0 days 
[IQR 2·5–18·5]). Urinary debris occurred in 14 men (34%, 95% CI 20–51), with a median duration of 14·5 days 
(IQR 6·0–16·5). Urinary tract infection was noted in seven men (17%, 95% CI 7–32). Median overall International 
Index of Erectile Function-15 (IIEF-15) scores were similar at baseline and at 12 months (p=0·060), as were median 
IIEF-15 scores for intercourse satisfaction (p=0·454), sexual desire (p=0·644), and overall satisfaction (p=0·257). 
Signiﬁ cant deteriorations between baseline and 12 months were noted for IIEF-15 erectile (p=0·042) and orgasmic 
function (p=0·003). Of 35 men with good baseline function, 31 (89%, 95% CI 73–97) had erections suﬃ  cient for 
penetration 12 months after focal therapy. Median UCLA Expanded Prostate Cancer Index Composite (EPIC) urinary 
incontinence scores were similar at baseline as and 12 months (p=0·045). There was an improvement in lower 
urinary tract symptoms, assessed by International Prostate Symptom Score (IPSS), between baseline and 12 months 
(p=0·026), but the IPSS-quality of life score showed no diﬀ erence between baseline and 12 months (p=0·655). All 
38 men with no baseline urinary incontinence were leak-free and pad-free by 9 months. All 40 men pad-free at 
baseline were pad-free by 3 months and maintained pad-free continence at 12 months. No signiﬁ cant diﬀ erence was 
reported in median Trial Outcomes Index scores between baseline and 12 months (p=0·113) but signiﬁ cant 
improvement was shown in median Functional Assessment of Cancer Therapy (FACT)-Prostate (p=0·045) and 
median FACT-General scores (p=0·041). No histological evidence of cancer was identiﬁ ed in 30 of 39 men biopsied 
at 6 months (77%, 95% CI 61–89); 36 (92%, 79–98) were free of clinically signiﬁ cant cancer. After retreatment in four 
men, 39 of 41 (95%, 95% CI 83–99) had no evidence of disease on multiparametric MRI at 12 months.
Interpretation Focal therapy of individual prostate cancer lesions, whether multifocal or unifocal, leads to a low rate of 
genitourinary side-eﬀ ects and an encouraging rate of early absence of clinically signiﬁ cant prostate cancer.
Funding Medical Research Council (UK), Pelican Cancer Foundation, and St Peters Trust.
Introduction
The management of localised prostate cancer remains 
controversial because the systematic over-diagnosis that 
accompanies the current diagnostic pathway results in 
over-treatment.1 At present, radical whole-gland surgery 
or radiotherapy can result in substantial side-eﬀ ects that 
are a consequence of damage to surrounding structures. 
These include urinary incontinence (5–20%), erectile 
dysfunction (30–70%), and bowel toxicity (5–10%).2,3 
Technological reﬁ ne ments do not seem to have reduced 
the burden of harm.4,5
Apart from active surveillance for low-risk disease, 
few strategies are available to address the burden of 
treatment-related side-eﬀ ects in other risk categories. 
One strategy that has shown promise relates to 
managing prostate cancer in the same manner as 
most other solid organ malignancies—by focusing 
the therapy to the cancer lesion, injury to the 
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bladder, rectum, and neurovascular bundles could be 
reduced.6,7
We have previously assessed hemi-ablation of patients 
with localised unilateral prostate cancer,8 which included 
treatment of the entire half of the prostate associated 
with cancer. Regardless of the grade, volume, or location 
of cancer that aﬀ ected half of the prostate, the entire side 
was ablated. This strategy is the most straight forward to 
undertake, standardise, and train others to do, but is 
limited because only one in ﬁ ve men have true unilateral 
disease on template biopsies. Furthermore, hemi-ablation 
might represent overtreatment since a low-volume, low-
grade lesion would be treated in the same manner as a 
high-volume, high-grade cancer. In this study, we 
postulated that selective focal ablation of unifocal and 
multifocal cancer lesions with a margin of normal tissue 
could reduce genitourinary and rectal side-eﬀ ects for 
men with localised prostate cancer.
Methods
Study design and patients
We undertook a two-centre, prospective development 
study, as deﬁ ned by the IDEAL (Idea, Development, 
Exploration, Assessment, and Long-term) guidelines for 
assessing innovation in surgery.9 Men could enter into 
the study if they had localised prostate cancer on 
multiparametric MRI and transperineal template-
prostate-mapping biopsies.10
We included men with low-risk to high-risk disease 
(prostate-speciﬁ c antigen [PSA] ≤15 ng/mL, Gleason 
score ≤4+3, stage ≤T2), aged 45–80 years with a life 
expectancy of 5 years or more, a prostate volume of 40 mL 
or less or maximum anterior–posterior length of 40 mm 
or less who had undergone multiparametric MRI and 
transperineal template (5 mm spaced) biopsies in the 
6 months before recruitment. We excluded men who had 
androgen suppression within the previous 6 months, 
previous radiation therapy or chemotherapy for prostate 
cancer, latex allergies, previous rectal surgery preventing 
insertion of transrectal probe, intraprostatic calciﬁ cations 
making high-intensity focused ultrasound (HIFU) of 
focal areas of cancer diﬃ  cult, previous transurethral 
resection of the prostate or laser prostatectomy in 5 years 
before recruitment, previous HIFU, cryosurgery, or 
thermal or microwave therapy to the prostate at any point 
before recruitment. Men who were not ﬁ t for general 
anaesthesia or regional anaes thesia as assessed by a 
consultant anaesthetist, or were unable to have MRI 
scanning (eg, severe claustrophobia, permanent cardiac 
pacemaker, metallic implant likely to contribute 
signiﬁ cant artifact to images) were also excluded. All 
men gave written informed consent.
Our trial was approved by the University College 
London Hospitals Local Research Ethics Committee A, 
UK, which is under the auspices of the National Research 
Ethics Service. The study was independently audited by 
hospital research and development oﬃ  cials. Additionally, 
the protocol was anonymously peer-reviewed by the 
National Cancer Research Network (NCRN), UK, and the 
Medical Research Council, UK.
Procedures
To locate areas of cancer, multiparametric MRI was done 
at 1·5 T magnetic ﬁ eld strength with pelvic phased-array 
coils. Sequences included T2-weighting, dynamic 
gadolinium contrast-enhance ment and diﬀ usion-
weighting. Template-prostate-mapping biopsies were 
done under general or spinal anaesthesia with the 
prostate sampled at 5 mm intervals. Two biopsies were 
taken at the same grid coordinate if the prostate was 
longer than the standard length of a biopsy core. All 
biopsies were reported by a single uropathologist.
Men underwent focal ablation with a transrectal HIFU 
device (Sonablate 500; Focus Surgery, Indianapolis, IN, 
USA). Ultrasonic waves were generated with a cylindrical 
piezoelectric ceramic transducer and then focused with a 
spherical plate onto a target area determined by the focal 
length of the transducer. The sound waves were 
transmitted to the tissues by a coupling mechanism from 
a transducer placed either extracorporeally or transrectally. 
Transmission of sound waves transrectally was achieved 
by placing the probe in a condom ﬁ lled with chilled 
circulating degassed water. The dimensions of the target 
area were determined by the focal length of the transducer, 
the applied frequency, the intensity of the applied power 
(W/cm²), and the duration of the pulse. The lesion 
produced was pseudoellipsoid in shape and referred to as 
the focal zone. Its long axis lies at right angles to the 
transducer and is greatest in length towards the 
transducer.
Tissue destruction is produced by thermal, mechanical, 
and cavitation eﬀ ects to produce a clearly demarcated 
region of coagulative necrosis surrounded by normal 
tissue on microscopic examination. Thermal energy 
comes from absorption of mechanical energy. Adequate 
cell destruction can be produced by short exposure (1 s) 
to temperatures of 60°C or more, which has therefore 
been adopted as the minimum target temperature. In 
practice, this temperature is easily attained with 
temperatures of 80°C or more recorded during HIFU 
therapy. Cooling due to tissue perfusion in the focal zone 
is not a problem because the rate of heating is greater 
than that of cooling when the exposure time is within a 
window of 3 s. The mechanical eﬀ ects of HIFU are more 
complex and involve shear forces, torque, and streaming. 
These forces result in destruction by both physical and 
thermal means. Cavitation results from gas (bubble) 
formation within cells due to heat and mechanical energy 
deposition causing bubbles to oscillate.
All patients had sterile urine on culture before 
treatment. If culture was positive for infection, men were 
treated with antibiotics and their treatment rescheduled; 
prophy lactic intravenous gentamicin was given to all 
men at the time of general anaesthetic. A suprapubic 
For the study protocol see 
https://www.ucl.ac.uk/focal/
therapy/hifu/focal/Focal-HIFU-
Protocol
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catheter was inserted before HIFU under the same 
anaesthetic.
We standardised the process of focal therapy by setting 
three broad guidelines. First, a maximum of 60% of the 
prostate could be ablated. Second, the edge of the ablation 
zone had to be at least 10 mm from a neurovascular 
bundle. The ablation zone had to be at least 5 mm from 
both neurovascular bundles if disease was bilateral. Third, 
untreated areas could not have any histological evidence 
of prostate cancer; high-grade prostate intraepithelial 
neoplasia and atypical small acinar proliferation were 
permitted. The operator made judgments as to the 
location and boundaries of the cancer lesions for 
treatment planning on the basis of the information from 
both multiparametric MRI (when a lesion was visible) 
and template-prostate-mapping biopsies. The areas 
positive for cancer were treated with at least a 3–5 mm 
margin around the lesion (2–4 HIFU pulses). In areas 
where a discrepancy between multi parametric MRI and 
template-prostate-mapping biopsies was identiﬁ ed, 
histopathological ﬁ ndings took prece dence. Some cancer 
lesions were quite close and were therefore included in 
the same area of treatment. As a result, more than two 
lesions could be treated as long as there were only two 
areas of treatment. Designation of individual lesions was 
usually straightforward but when positive biopsies were 
close together, lesions were labelled separately if there 
was at least one intervening normal biopsy.
After ablation, the suprapubic catheter was placed on 
free drainage into a urinary leg-bag for 1–2 days and 
urethral voiding was encouraged thereafter by closure of 
a valve attached to the catheter. Because many men 
travelled a long distance, the timing of catheter removal 
was delayed to coincide with the ﬁ rst trial visit after the 
operation at 10–14 days (for an early MRI) even if urethral 
voiding was restored earlier. All men were given 
ciproﬂ oxacin and oral analgesia (co-dydramol) for 7 days. 
A contrast-enhanced MRI was done 10–14 days after focal 
HIFU to conﬁ rm the area of ablation, as shown by a 
conﬂ uent perfusion deﬁ cit.
Follow-up consisted of clinic visits at 1 month, 
3 months, 6 months, 9 months, and 12 months for 
PSA measurement and adverse event reporting. Men 
ﬁ lled in validated questionnaires at each clinic visit. 
Questionnaires included the International Prostate 
Symptom Score (IPSS), International Index of Erectile 
Function-15 (IIEF-15), UCLA-Expanded Prostate Cancer 
Index Composite (EPIC) urinary incontinence scale, 
and the Functional Assessment of Cancer Therapy-
Prostate (FACT-P) score, which includes FACT-General 
(FACT-G) scores and the Trials Outcome Index.11–15 
Phosphodiesterase-5 inhibitors were permitted at any 
timepoint during follow-up. At 6 months, another 
multiparametric MRI followed by targeted biopsies of 
the treated areas were scheduled with a minimum 
requirement for sampling every 1 mL of residual tissue 
with one core. Our justiﬁ cation for one biopsy for every 
mL of residual tissue reﬂ ects the biopsy density of the 
original template biopsies before focal HIFU (which 
was about 1 mL for every biopsy). Retreatment with a 
further focal HIFU was permitted if biopsies were 
positive. A further multi parametic MRI scan was done 
at 12 months. As the purpose of the 6-month biopsies 
was to determine whether the ablation was successful, 
our ethics com mittee did not permit sampling of 
untreated tissue due to the requirement for another 
general anaesthetic. However, biopsies of the untreated 
tissue were permitted if a new, potentially malignant 
lesion was seen on multiparametric MRI.
The primary outcomes were feasibility, patient 
acceptability, and side-eﬀ ect proﬁ le of focal HIFU. 
Feasibility and acceptability were reported with rates and 
description of adverse events, serious and otherwise. 
Urinary symptoms and erectile function were assessed 
with patient questionnaires. The IIEF-15 was used to 
report the proportion of men capable of having erectile 
function suﬃ  cient for penetration at 12 months as well as 
total IIEF-15 score and domain scores on erectile function, 
intercourse satisfaction, orgasmic function, sexual desire, 
and overall satisfaction. Urinary function was assessed 
with IPSS, the IPSS quality-of-life questionnaire, and the 
UCLA EPIC continence questionnaire. The continence 
questionnaire included total scores as well as the 
proportion of patients who were pad-free, or leak-free and 
pad-free at 12 months. Quality of life was measured with 
FACT-P with summary measures of the Trial Outcome 
Index score, FACT-P score, and FACT-G score.
Secondary outcomes were histological and imaging 
measures of cancer control. A composite outcome in the 
form of trifecta status was assessed at 12 months. For this 
status to be met, we deﬁ ned trifecta as leak-free and pad-
free continence, erections suﬃ  cient for penetration, and 
no evidence of clinically signiﬁ cant disease at 12 months 
multiparametric MRI16,17 in those men with normal 
baseline genitourinary function.
Statistical analysis
Since the primary objective of the study was to determine 
the side-eﬀ ect proﬁ le of focal ablation, the sample size 
was powered on a common event, namely erectile 
dysfunction. We estimated that focal ablation therapy 
would lead to an absolute rate of 15% erectile dysfunction 
(insuﬃ  cient for penetrative sex) at 12 months. The 
sample size calculation was based on a comparison with 
a known rate of 40% erectile dysfunction,18 which usually 
occurs when HIFU is applied to the whole prostate.19 
Therefore, with an α level of 0·05 and power of 90% 
(1–β), the sample size required was at least 33 men with 
good baseline function. We adjusted the sample size to 
allow for the estimated rate of 25% of men having poor 
baseline erectile function in the general population, and 
therefore aimed to recruit 42 men in total.
Validated questionnaires were analysed with standard 
methods. Missing values for patient-reported outcome 
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variables (between 2% and 10% missing values for 
individual questions) were imputed with a fully con-
ditional speciﬁ cation method and logistic regression 
model (categorical data). The imputation was based on 
the observation of values missing completely at random. 
We classed the variables for which missing values were 
to be imputed (questionnaires) as categorical. Therefore, 
logistic regression was used with available values of 
the same variables at diﬀ erent timepoints either side of 
the imputed value as predictors. Imputed values were 
rounded up to next integer values. Maximum and 
minimum values were set according to extremes of 
questionnaire item scales.
Categorical outcomes were reported as point estimates 
with binomial 95% CIs to demonstrate level of precision. 
Wilcoxon signed rank test (two-tailed) was used to assess 
diﬀ erences between continuous variables that were not 
normally distributed (PSA and questionnaire scores) 
measured at baseline and at the 12-month follow-up visit. 
Changes over time were reported with box-and-whisker 
plots. Subgroup analyses were hypothesis-generating 
and with small numbers in each subgroup, it was 
deemed inappropriate to run statistical tests of signiﬁ -
cance in such comparisons. p values of 0·05 or less were 
deemed signiﬁ cant. All statistical tests were done with 
SPSS (version 17.0). This study is registered with 
ClinicalTrials.gov, number NCT00561314.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. HUA, LD, RS, JvdM, and ME had 
access to the raw data. The corresponding author had full 
access to all the data and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
42 men were recruited between June 27, 2007, and 
June 30, 2010. One man had an unrelated death 
3 months after focal therapy. He had baseline retro-
peritoneal ﬁ brosis, hypertension, and a single kidney. He 
had an uneventful recovery after HIFU and had no 
respiratory symptoms immediately before treatment, or 
at 2 weeks and 6 weeks after treatment during the formal 
trial visits. The cause was independently veriﬁ ed by local 
physicians as respiratory failure following pneumonia. 
As a result, 41 men were included in analyses; 30 (73%) 
had intermediate and high-risk disease (table 1).20 Three 
men had baseline mild stress urinary incontinence but 
required no pads; 35 had good baseline sexual function 
with erections suﬃ  cient for penetration. Of 41 men, 
20 (49%) had unilateral, one-area ablation, 15 (37%) had 
bilateral, two-area ablation, and six (15%) had midline, 
one-area treatment (ﬁ gure 1). Baseline characteristics of 
these three groups are shown in the appendix.
30 (73%, 95% CI 57–86) men had a hospital stay of less 
than 24 h. All 41 were able to void urine through the 
Patients (N=41)
Age (years) 63 (58·0–66·0)
Serum PSA (ng/mL) 6·6 (5·4–7·7)
Reason for PSA test and biopsy
PSA screening (patient request) 31 (76%)
Lower urinary tract symptoms* 10 (24%)
Prostate volume (mL) 35 (29·0–45·5)
PSA density (ng/mL per mL prostate) 0·18 (0·14–0·22)
Initial biopsy
TRUS biopsy 35 (85%)
TPM biopsy 6 (15%)
Gleason (TRUS-guided biopsy)
3+3 24 (59%)
3+4 7 (17%)
4+3 5 (12%)
No TRUS biopsy 5 (12%)
Gleason (TPM biopsies)
3+3 13 (32%)
3+4 24 (59%)
4+3 4 (10%)
Clinical stage
T1c 37 (90%)
T2a 4 (10%)
TRUS guided biopsies
Total cores 10·0 (8·0–12·0)
Total positive cores 2·0 (1·0–3·0)
Percent positive cores 11·0 (6·3–33·8)
TPM biopsies
Total cores 46 (35·5–65·5)
Total positive cores† 5 (3·0–9·0)
Positive cores (%) 9·4% (4·6–18·5)
Core density (biopsies/mL) 1·4 (0·9–1·9)
Number of lesions on TPM
One 21
Two 17
Three 3
Disease distribution
Unifocal
Unilateral 15 (37%)
Bilateral (midline lesion) 6 (15%)
Multifocal
Unilateral 5 (12%)
Bilateral 15 (37%)
NCCN risk category20
Low 11 (27%)
Intermediate 26 (63%)
High 4 (10%)
Data are median (IQR), number, or number (%). PSA=prostate-speciﬁ c antigen. 
TRUS=transrectal ultrasound. TPM=template prostate mapping. NCCN=National 
Comprehensive Cancer Network. *These men were opportunistically screened 
with a PSA test when they presented with symptoms of lower urinary tract 
infection, rather than part of a formal request (by their physician or by the men 
themselves) for a PSA test. †A high number of positive cores were retrieved, 
despite only a maximum of three lesions, because large dominant lesions were 
sampled several times.
Table 1: Baseline characteristics
See Online for appendix
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urethra on the ﬁ rst day after the operation with the 
suprapubic catheter clamped. About a ﬁ fth had self-
resolving, mild to moderate, intermittent dysuria 
(table 2). One man had acute retention of urine 3 days 
after removal of the suprapubic catheter, which required 
a urethral catheter for 5 days. In terms of rectal adverse 
events, one man had diarrhoea and mucus discharge 
2 weeks after focal HIFU while the suprapubic catheter 
was still in situ. He had multiparametric MRI and 
urethrogram within 4 weeks, which showed extravasation 
of urine outside the prostate; although the serosal layer 
of the rectum was aﬀ ected by treatment no deﬁ nitive 
rectourethral ﬁ stula was seen. However, as a precau-
tionary measure, he was managed conservatively with a 
suprapubic catheter and quinolone antibiotics, serial 
2 monthly multiparametric MRI, and a further repeat 
urethrogram until the extravasation had resolved by 
6 months. At that point, he developed a stricture 
requiring endoscopic dilatation; a further two limited 
endoscopic prostate-tissue resections to a prostate that 
had a total volume of 80 mL were done when voiding did 
not return to normal.
Overall IIEF-15 scores initially decreased, indicating 
diminished erectile function but showed a gradual return 
to baseline by 12 months (p=0·060; ﬁ gure 2A). IIEF-15 
domain scores in intercourse satisfaction (p=0·454), 
sexual desire (p=0·644), and overall satisfaction (p=0·257) 
all showed decreased scores at 1 month and 3 months, 
but there was no signiﬁ cant diﬀ erence between baseline 
and 12 months (ﬁ gure 2 C, F). IIEF-15 erectile and 
orgasmic domains showed signiﬁ cant deteriorations 
from baseline to 12 months (p=0·042 and p=0·003, 
respectively; ﬁ gure 2 B, D). Of 35 men with erectile 
function satisfactory for penetration before treatment, 
31 (89%, 95% CI 73–97) described erections suﬃ  cient for 
penetration at 12 months. No formal programme of 
penile rehabilitation was available, but all men were 
oﬀ ered phosphodiesterase-5 inhibitors (eg, sildenaﬁ l, 
tadalaﬁ l) if needed; 14 of the 31 men required phospho-
diesterase-5 inhibitors.
In a post-hoc analysis to explore whether type of 
ablation made any diﬀ erence to erectile dys function, we 
assessed the following factors. Of those men who had 
erections suﬃ  cient for penetration at baseline, 28 of 
31 (90%, 95% CI 74–98) of those who had unilateral nerve-
sparing ablation and four of four (100%, 40–100) who had 
bilateral nerve-sparing ablation had erections suﬃ  cient 
for penetration at 12 months. Although only six patients 
received midline nerve-sparing ablation, we assessed the 
hypothesis that bilateral ablation might result in higher 
erectile dysfunction rates than unilateral ablation. Of 
those men who had erections suﬃ  cient for penetration at 
baseline, 17 of 18 (94%, 95% CI 73–100) who had unilateral 
Figure 1: Schematic diagrams of the types of focal therapy
Unilateral one-area ablation (A). Bilateral two-area ablation with preservation of one neurovascular bundle (B). Midline one-area ablation allows preservation of both 
neurovascular bundles (C). Large red areas represent dominant cancers (index lesions) whereas small green areas represent small low-grade secondary lesions. Grey 
transparent boxes represent ablation zones on the high-intensity focused ultrasound device.
Neurovascular bundles
BA C
Value
Total anaesthetic time (min) 135·0 (115·0–150·0)
Procedure time (Suprapubic catheter+focal HIFU; min) 105·0 (87·0–125·0)
Total hospitalisation time (admission to discharge; h) 12·0 (10·0–27·0)
Discharge time (end procedure to discharge; h) 6·0 (5·0–18·0)
Time with suprapubic catheter (days)*† 8·5 (8·0–15·0)
Dysuria (negative urine culture) 9/41 (22%, 11–38)
Duration of dysuria (days) 5 (2·5–18·5)
Intermittent haematuria (start of stream only) 16/41 (39%, 24–56)
Duration of intermittent haematuria (days) 15 (10·3–15·0)
Urinary debris 14/41 (34%, 20–51)
Duration of urinary debris (days) 14·5 (6·0–16·5)
Urinary tract infection (positive urine culture) 7/41 (17%, 7–32)
Acute retention of urine 1/41 (2%, 0–13)
Data are median (IQR) or number of patients aﬀ ected/N (%, 95% CI). HIFU=high-intensity focused ultrasound. 
*Suprapubic catheter was usually removed at the same time as the postoperative early contrast MRI for convenience to 
reduce visits for men who travelled far to the study centre. †The man who had diarrhoea and mucus discharge and had 
a suprapubic catheter for 6 months was excluded from these descriptive values. 
Table 2: Perioperative outcomes in men undergoing focal high-intensity focused ultrasound for unifocal 
and multifocal localised prostate cancer
Articles
www.thelancet.com/oncology   Vol 13   June 2012 627
ablation and 15 of 17 (88%, 95% CI 64–99) who had 
bilateral or midline ablation had erections suﬃ  cient for 
penetration at 12 months.
UCLA EPIC urinary incontinence scores showed an 
initial deterioration in continence function but had 
returned to a similar value as at baseline by 12 months 
Figure 2: Sexual function after focal high-intensity focused ultrasound for unifocal and multifocal localised prostate cancer, measured with the International 
Index of Erectile Function-15 (IIEF-15) questionnaire
Two-tailed p values were reported for Wilcoxon signed ranks test comparing baseline and 12-month median scores. Box and whiskers plots indicate median with IQR 
(boxes), and range (whiskers). Dots are outliers. Median baseline versus 12-month scores: total IIEF-15 (57·5 [IQR 30·0–67·0] vs 47·0 [29·5–63·3], p=0·060; A); IIEF-15 
erectile-function domain (24·0 [13·0–29·0] vs 21·0 [10·3–27·3], p=0·042; B); IIEF-15 intercourse-satisfaction domain (9·0 [0·0–12·0] vs 8·0 [0·0–11·0], p=0·454; C); 
IIEF-15 orgasmic-function domain (10·0 [6·5–10·0] vs 7·0 [5·0–8·5], p=0·003; D); IIEF-15 sexual-desire domain (7·0 [5·0–8·5] vs 7·0 [5·0–8·0], p=0·644; E); IIEF-15 
overall-satisfaction domain (7·5 [4·0–9·0] vs 8·0 [6·0–9·0], p=0·257; F).
80
60
40
20
0
–20
   N=41              N=41            N=41            N=41             N=41             N=41 40
30
20
10
0
–10
–20
      N=41             N=41            N=41            N=41             N=41             N=41
15
10
5
0
–5
       N=41             N=41            N=41            N=41             N=41             N=41 15
10
5
0
–5
       N=41             N=41            N=41            N=41              N=41             N=41
10
8
6
4
2
0
      N=41            N=41            N=41             N=41             N=41            N=41
12
9
6
3
0
      N=41            N=41             N=41             N=41            N=41             N=41
O
ve
ra
ll 
IIE
F 
sc
or
e
IIE
F 
er
ec
til
e 
fu
nc
tio
n 
sc
or
e
IIE
F 
in
te
rc
ou
rs
e 
sa
tis
fa
ct
io
n 
sc
or
e
IIE
F 
or
ga
sm
ic 
fu
nc
tio
n 
sc
or
e
IIE
F 
se
xu
al
 d
es
ire
 sc
or
e
IIE
F 
ov
er
al
l s
at
isf
ac
tio
n 
sc
or
e
Time (months)
1231 90 6
Time (months)
1231 90 6
(n=2)
(n=2)
(n=3)
(n=1) (n=1)
(n=1)
(n=1)
BA
DC
FE
Articles
628 www.thelancet.com/oncology   Vol 13   June 2012
(p=0·045; ﬁ gure 3). IPSS values increased initially 
although by 12 months showed signiﬁ cantly lower values, 
suggesting improvement in lower urinary-tract 
symptoms from baseline (p=0·026; ﬁ gure 4). No 
signiﬁ cant diﬀ erence was seen in IPSS-quality-of-life 
score between baseline and 12 months (p=0·655; 
ﬁ gure 4). Of 38 men with no urinary leak at baseline all 
(100%, 95% CI 91–100) were leak-free and pad-free by 
9 months; 40 men pad-free at baseline were pad-free 
again by 3 months and maintained pad-free continence 
at 12 month (100%, 91–100; one man did not report on 
this parameter at 12 months and was excluded).
Signiﬁ cant deterioration of health-related quality of life 
was shown between baseline and 12 months on the total 
FACT-P and total FACT-G scores (p=0·045 and p=0·041, 
respectively; ﬁ gure 5). No signiﬁ cant diﬀ erence was seen 
between baseline and 12 months in the Trial Outcomes 
Index between baseline and 12 months (p=0·113; 
ﬁ gure 5).
Compared with baseline, a signiﬁ cant decrease in PSA 
levels was reported at 12 months (p<0·0001; ﬁ gure 6). 
The time to nadir was not calculated because the PSA 
changes showed a pattern of ongoing small decreases in 
PSA up to trial end at 12 months.
One man refused to undergo biopsy at 6 months 
because of his concern over the eﬀ ect of further biopsies 
on sexual function. The man with diarrhoea and rectal 
mucus discharge was excluded from biopsy because of 
risk of infection and promotion of ﬁ stula formation. Both 
had multiparametric MRI at 6 months, which showed no 
evidence of disease. The second man had transurethral 
resection of obstructing prostate tissue at 7 months, 
which was histologically conﬁ rmed as benign. Of the 
39 men biopsied, nine (23%, 95% CI 11–39) had evidence 
of cancer while three (8%, 2–21) had evidence of clinically 
signiﬁ cant cancer (Epstein criteria21,22—Gleason >3 + 3, 
>2 cores positive, >2 mm cancer involve ment; table 3). 
All biopsies done after focal HIFU had one or more of 
the following features: necrosis, ﬁ brosis, or giant-cell 
reaction. Presence of these features showed that treated 
areas were accurately targeted. Multiparametric MRI at 
6 months showed signs of residual cancer in the treated 
areas in nine men; seven of whom had cancer conﬁ rmed 
on biopsy. Two men with negative multiparametric MRI 
but positive biopsies both had clinically insigniﬁ cant 
disease. No areas of residual cancer were identiﬁ ed in 
untreated areas on multiparametric MRI so untreated 
areas were not biopsied.
Of those men with positive biopsies at 6 months, ﬁ ve 
chose to undergo active surveillance and four had 
Figure 3: Continence function after focal high-intensity focused ultrasound for 
unifocal and multifocal localised prostate cancer, measured with UCLA 
Expanded Prostate Cancer Index Composite (EPIC) incontinence questionnaire
Two-tailed p values were reported for Wilcoxon signed ranks test comparing 
baseline and 12-month median scores. Median baseline vs 12 month scores: 
100 (IQR 86·0–100·0) vs 100 (92·5–100·0, p=0·045). Box and whiskers plots 
show median with IQR (boxes) and range (whiskers). Dots are outliers.
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Figure 4: Urinary function after focal high-intensity focused ultrasound for 
unifocal and multifocal localised prostate cancer, measured with 
International Prostate Symptom Score (IPSS) questionnaire
Two-tailed p values were reported for Wilcoxon signed ranks test comparing 
baseline and 12-month median scores. Box and whiskers plots show median 
with IQR (boxes) and range (whiskers). Dots are outliers. Median baseline versus 
12-month International Prostate Symptom Score (IPSS): 8·0 (IQR 5·5–13·0) vs 
7·0 (3·0–12·0, p=0·026; A). Median baseline versus 12-month IPSS-quality of life: 
1·0 (0·0–2·0) vs 1·0 (1·0–1·0, p=0·655; B).
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retreatment. PSA levels in the retreatment group 
changed from a median of 3·9 ng/mL (IQR 3·7–4·5) at 
6 months (before retreatment) to 3·9 ng/mL (3·7–4·1) at 
9 months and 2·9 ng/mL (1·8–3·6) at 12 months. None 
of the four men undergoing repeat focal therapy 
consented to further biopsies but all had multiparametric 
MRI at trial exit showing no evidence of clinically 
signiﬁ cant disease at 12 months. No man required 
adjuvant radiotherapy, prostate cancer surgery, or 
androgen deprivation therapy during the trial duration.
Figure 6: PSA levels after focal high-intensity focused ultrasound for unifocal 
and multifocal localised prostate cancer
Wilcoxon signed ranks test comparing median prostate-speciﬁ c antigen levels at 
baseline (6·6 [IQR 5·4–7·7] ng/mL) and at 12 months (1·9 [0·8–3·3] ng/mL; 
two-tailed p<0·0001). Box and whiskers plots show median with IQR (boxes) 
and range (whiskers). Dots are outliers.
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Figure 5: Quality-of-life outcomes after focal high-intensity focused 
ultrasound for unifocal and multifocal localised prostate cancer, measured 
with the Functional Assessment of Cancer Therapy (FACT) questionnaire
Two-tailed p values were reported for Wilcoxon signed ranks test comparing baseline 
and 12-month median scores. Box and whiskers plots show median with IQR (boxes) 
and range (whiskers). Dots are outliers. Median baseline versus 12-month Trials 
Outcome Index score: 94·0 (IQR 89·0–97·3) vs 97·5 (91·0–101·0, p=0·113; A). Median 
baseline versus 12-month Functional Assessment of Cancer Therapy (FACT)-Prostate 
score: 138·5 (133·0–147·0) vs 145·3 (137·0–152·0, p=0·045; B). FACT-general score: 
96·0 (91·0–102·3) vs 102·0 (96·0–105·0, p=0·041; C).
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Value
Number of cores taken 6·0 (5·0–7·0)
Absence of any cancer 30/39 (77%, 61–89)
Positive biopsy outcomes*
Positive biopsies† 9/39 (23%, 11–39)
Maximum cancer core length (in positive 
cores), mm
1·0 (1·0–3·5)
Gleason (N)
3+3 6
3+4 3
Absence of clinically signiﬁ cant disease‡ 36/39 (92%, 79–98)
Other histological ﬁ ndings
Prostatic acini 21/39 (54%, 37–70)
Atrophy 25/39 (64%, 47–79)
Fibrosis 35/39 (90%, 76–97)
Giant-cell reaction 4/39 (10%, 3–24)
Necrosis 15/39 (38%, 23–55)
Data are median (IQR) or number of patients/N (%, 95% CI). *Two men were not 
biopsied because of suprapubic catheter in situ in one patient and refusal by 
another. †Five men opted for surveillance. Of these, four had 1 mm of Gleason 
3+3 and one had 2 mm of Gleason 3+4. Four men opted for retreatment. Of these, 
two had clinically signiﬁ cant cancer (5 mm and 6 mm of Gleason 3+4) and two 
had no more than 1 mm of Gleason 3+3. ‡As deﬁ ned by Epstein criteria: Gleason 
>3+3, >2 cores positive, ≥3 mm cancer involvement.
Table 3: Histological outcomes at 6 months in men undergoing focal 
high-intensity focused ultrasound for unifocal and multifocal localised 
prostate cancer
Articles
630 www.thelancet.com/oncology   Vol 13   June 2012
Of the 31 men with good baseline function, 26 (84%, 
95% CI 66–95) achieved the trifecta status of having 
leak-free and pad-free continence, erections suﬃ  cient 
for intercourse, and no evidence of clinically signiﬁ cant 
disease on multipara metric MRI at 12 months 
(ﬁ gure 7). 
Discussion
To our knowledge, our study is the ﬁ rst to assess targeting 
of individual known cancer areas, with a margin of normal 
tissue, in men with multifocal as well as unifocal prostate 
cancer across all cancer-risk categories. Focal therapy of 
discrete areas of cancer, whether unifocal or multifocal, is 
feasible, safe, and can be delivered in an ambulatory care 
setting. Early self-resolving lower urinary-tract symptoms 
were common. However, the strategy was well tolerated in 
the genitourinary functional domains. Almost 90% of 
men reported having erections satisfactory for intercourse 
at 12 months, and all were continent.
There was a signiﬁ cant decrease in PSA levels from 
baseline to 12 months, with concentrations of serum 
PSA continuing to decline months after the initial 
treatment. This prevents an estimate of time to PSA 
nadir. Conclusions from this ﬁ nding should not be made, 
although if this decline in serum PSA were to be 
reproduced, one possible reason for it might be the 
presentation of antigens to the immune response leading 
to a secondary immune response against the remaining 
prostate tissue.23
There are several limitations to our study. First, the 
number of participants included in the study was small. 
As a prospective development study representing stage 
2b of the IDEAL guidelines for evaluating novel surgical 
strategies,24 we designed our trial to primarily assess side-
eﬀ ects. Second, characterisation of disease with template-
prostate-mapping biopsies before focal therapy was 
diﬀ erent to the 6-month veriﬁ cation biopsy, because of 
research ethics committee stipulations to limit patient 
burden. We have recently started recruiting patients to a 
multicentre, phase 2 trial that will address some of the 
legitimate concerns regarding the natural history of 
untreated prostate tissue. The trial will assess focal HIFU 
applied to clinically signiﬁ cant areas of prostate cancer 
identiﬁ ed on entry by multiparametric MRI and template 
prostate-mapping biopsies25,26 followed by further multi-
parametric MRI and template prostate-mapping biopsies 
applied to treated and untreated tissue at 3 years 
(NCT01194648). Third, our focal therapeutic strategy 
included ablation of normal surrounding tissue, which 
might contribute to the adverse events reported in our 
study. Destruction of some normal tissue is necessary to 
incorporate an adequate margin but because of the 
nature of the HIFU therapy, our margins are likely to be 
larger than they need to be. Other ablative modalities 
could serve to reduce the margins of ablated normal 
tissue. Furthermore, image-registration of preoperative 
MRI to treatment delivery could further help to reduce 
destruction of normal tissue by allowing the clinician to 
more accurately deﬁ ne the boundaries of the target 
lesion.
Many retrospective case series have reported 
encouraging short-term functional and cancer-control 
outcomes of men treated in a focal manner with HIFU 
and cryotherapy.27–32 A prospective feasibility trial has 
reported on the use of focal interstitial laser therapy in a 
small cohort of 12 men with very low-risk unifocal 
disease.33 We have previously reported8 the outcomes 
from a prospective development study of 20 men with 
unilateral disease undergoing ablation of an entire 
prostate lobe using HIFU. 18 (90%) were leak-free and 
pad-free continent while 19 (95%) were pad-free after 
Figure 7: Trifecta rate after focal high-intensity focused ultrasound for unifocal and multifocal localised 
prostate cancer
Patient-reported trifecta outcomes were reported with validated questionnaires. Data are number of patients 
(%, 95% CI). *Derived using UCLA EPIC urinary domain questions: “over the past 4 weeks how often do you leak 
urine?” and “over the past 4 weeks how many pads or adult diapers per day did you usually use to control leakage?”. 
†Before imputation of data, 36 of 36 men were leak-free and pad-free. ‡Before imputation of data, 38 of 38 men 
were pad-free. §Proportion of men scoring ≥2 on question 2 of IIEF-15: “over the past 4 weeks when you had 
erections with sexual stimulation, how often were your erections hard enough for penetration?”. ¶Before 
imputation of data, 29 (88%) of 33 men had erections suﬃ  cient for penetration. ||Phosphodiesterase-5 inhibitors 
(tadalaﬁ l, sildenaﬁ l, or vardenaﬁ l; percentage calculated with denominator as those achieving erections suﬃ  cient 
for intercourse).
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hemi-ablation; 17 (89%) of 19 achieved trifecta status at 
12 months.8
The current study allowed user or operator deter-
mination of ablative zones within the prostate on an 
individual basis provided our standardised method of 
focal therapy was followed. However, the treatments 
invariably followed one of three patterns of ablation 
(ﬁ gure 1), by contrast with our previous study,8 whereby 
the treatment method was ﬁ xed and standardised by 
mandating therapy to the entire half of the prostate 
associated with cancer (hemi-ablation) regardless of 
individual lesion grade, volume, or location and proximity 
to a neurovascular bundle.
While our current study is not directly comparable to 
previous studies of focal therapy (panel), it continues to 
support the proposition that tissue preservation leads to 
functional preservation. The histological outcomes in this 
study were slightly worse than those reported for hemi-
ablation, perhaps because of the requirements for 
increased pre cision of focal ablation—individual areas of 
cancer were targeted as opposed to a standardised hemi-
ablation—with a resulting reduction in margin around 
the cancer. Image-registration software to accurately fuse, 
in real-time, pretreatment location data to intraoperative 
ultrasound images could improve histological outcomes.34 
Another reasonable explanation might relate to physical 
limitations of the ablative technology. Other ablative 
therapies as well as brachy therapy35 and image-guided 
radiosurgery platforms are able to treat discrete volumes 
of tissue and might have diﬀ ering outcomes. New 
platforms such as irreversible electroporation and 
photodynamic therapy are theor etically more tissue-
speciﬁ c and could allow neurovascular bundle preservation 
even if the ablative zone is close to the prostate capsule; 
tissue speciﬁ city of these techniques has not yet been 
assessed.
In conclusion, focal therapy of individual prostate-
cancer lesions, regardless of whether they are multifocal 
or unifocal, leads to a low rate of genitourinary side-
eﬀ ects and an encouraging rate of early freedom from 
clinically signiﬁ cant prostate cancer. If the functional 
outcomes that we report are reproduced in larger 
studies and coupled with acceptable rates of cancer 
control in the medium to long term, focal therapy could 
oﬀ er a strategy by which the burden of treatment-
related side-eﬀ ects are addressed for a substantial 
proportion of men with localised prostate cancer. The 
design and execution of comparative-eﬀ ectiveness 
research assessing long-term cancer control needs to be 
prioritised, especially at a pace than can match the 
potential for informal diﬀ usion.
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Panel: Research in context
Systematic review
In 2007, we did a systematic review7 of reports on Medline and 
PubMed databases using the terms “focal therapy” and 
”prostate cancer” and/or “high intensity focused ultrasound” 
and/or “cryotherapy/cryoablation/cryosurgery”. We also 
searched for all prostate cancer clinical trials in the UK National 
Cancer Research Network portfolio, ClinicalTrials.gov, and 
ISRCTN trial registries. We only identiﬁ ed one prospective, 
commercially funded, phase 1 trial assessing photodynamic 
therapy in progress at the time. All other data were from two 
retrospective case series that were poorly reported. Subsequent 
to this review, we started a health technology assessment of 
focal therapy, following the phased approach described by the 
Medical Research Council complex interventions guidelines and 
subsequently formalised in the IDEAL guidelines for assessing 
surgical procedures.9
Interpretation
Our study showed that the rate of genitourinary side-eﬀ ects 
associated with focal therapy  is low, coupled with an 
encouraging rate of early absence of clinically signiﬁ cant 
prostate cancer. These ﬁ ndings reaﬃ  rm two other 
prospective development studies8,33 in which focal using 
high-intensity focused ultrasound and photothermal 
therapy was used.
Focal therapy could hold promise in mitigating the harms that 
result from current therapeutic strategies. Prioritisation and 
support of a pragmatic, randomised, clinical trial comparing focal 
therapy with whole-gland treatments is urgently needed. Such a 
trial should be done before informal diﬀ usion and dissemination 
of focal therapy. Any randomised controlled trial should be 
pragmatic in nature and adaptive in execution, so that actual 
clinical practice is reﬂ ected and new technological developments 
can be incorporated as they occur. Furthermore, since the natural 
history of prostate cancer is long, timelines based on metastases 
and mortality, which would require a trial at least 15 years in 
duration, might not be feasible or warranted. Therefore, 
endpoints that are clinically meaningful in the medium term are 
needed so that ﬁ ndings are delivered eﬃ  ciently and in a timely 
fashion to change practice. Subsequent linkage to national 
electronic registries will ensure that robust cancer-control 
outcomes are still reported at a later date.
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